| 12419937 |
High concentration alpha-glucosidase compositions for the treatment of Pompe disease |
Kenneth Valenzano, John Crowley, Richie Khanna |
2025-09-23 |
|
| 12208095 |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
Andrew P. Crew, Sheryl Maxine GOUGH, Royal J. HASKELL, III, Marcia Dougan MOORE, Yimin Qian +2 more |
2025-01-28 |
|
| 11808772 |
Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status |
ISABELLE BATXELLI-MOLINA, FLORIAN SALIPANTE, Roger Walker, JEANNETTE FAREH-MICHIEL |
2023-11-07 |
|
| 11439615 |
Lipoxin and lipoxin analogue mediated neuroprotection and treatments |
Jeremy M. Sivak, Izhar Livne-Bar, Karsten Gronert, Jessica Wei |
2022-09-13 |
|
| 11278599 |
High concentration alpha-glucosidase compositions for the treatment of Pompe disease |
Kenneth Valenzano, John Crowley, Richie Khanna |
2022-03-22 |
$4,357,000 |
| RE48608 |
Method to predict response to pharmacological chaperone treatment of diseases |
Elfrida Benjamin, Hung V. Do, Xiaoyang Wu, Brandon Wustman |
2021-06-29 |
|
| 10813921 |
Method to predict response to pharmacological chaperone treatment of diseases |
Elfrida Benjamin, Hung V. Do, Xiaoyang Wu, Brandon Wustman |
2020-10-27 |
$34,166,000 |
| 10512677 |
High concentration alpha-glucosidase compositions for the treatment of pompe disease |
Kenneth Valenzano, John Crowley, Richie Khanna |
2019-12-24 |
$13,091,000 |
| 10046033 |
High concentration alpha-glucosidase compositions for the treatment of Pompe disease |
Kenneth Valenzano, John Crowley, Richie Khanna |
2018-08-14 |
$28,277,000 |
| 9744188 |
Methods of promoting neuronal outgrowth by gypican 2 that binds to receptor protein tyrosine phosphatase sigma |
Yingjie Shen, Edith Yvonne Jones, Alexandru Radu Aricescu, Charlotte Hannah Coles |
2017-08-29 |
|
| 9545397 |
Method to predict response to pharmacological chaperone treatment of diseases |
Elfrida Benjamin, Hung V. Do, Xiaoyang Wu, Brandon Wustman |
2017-01-17 |
$6,970,000 |
| 9404100 |
High concentration alpha-glucosidase compositions for the treatment of Pompe disease |
Kenneth Valenzano, John Crowley, Richie Khanna |
2016-08-02 |
$10,639,000 |
| 9303249 |
High concentration α-glucosidase compositions for the treatment of Pompe disease |
Kenneth Valenzano, John Crowley, Richie Khanna |
2016-04-05 |
$22,311,000 |
| 9095584 |
Method to predict response to pharmacological chaperone treatment of diseases |
Elfrida Benjamin, Hung V. Do, Xiaoyang Wu, Brandon Wustman |
2015-08-04 |
$30,744,000 |
| 8592362 |
Method to predict response to pharmacological chaperone treatment of diseases |
Elfrida Benjamin, Hung V. Do, Xiaoyang Wu, Brandon Wustman |
2013-11-26 |
$2,812,000 |
| 8242256 |
siRNA useful to supress expression of EIF-5A1 |
John E. Thompson, Bruce C. Galton, Catherine Taylor, Adrienne Boone, Elizabeth Heikkila +3 more |
2012-08-14 |
$459,000 |
| 7662796 |
Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1 |
John E. Thompson, Bruce C. Galton, Catherine Taylor, Adrienne Boone, Elizabeth Heikkila +3 more |
2010-02-16 |
$98,000 |
| 7381708 |
Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye |
Catherine Taylor, Dominic Cliche, Elizabeth Heikkila, Diane Michelle Senchyna, John E. Thompson |
2008-06-03 |
|
| 6919313 |
Protein waving a PDZ and a RGS domain |
Qiang Lu, Edna E. Sun |
2005-07-19 |
$13,645,000 |
| 6777536 |
EPH receptor ligands, and uses related thereto |
Hwai-Jong Cheng |
2004-08-17 |
|
| 6399326 |
Nucleic acids encoding neural/pancreatic receptor tyrosine phosphatase |
Ming-Ko Chiang |
2002-06-04 |
|
| 6268476 |
EPH receptor ligands, and uses related thereto |
Hwai-Jong Cheng |
2001-07-31 |
|
| 5801000 |
Detection and isolation of receptors |
Philip Leder |
1998-09-01 |
|
| 5795734 |
EPH receptor ligands, and uses related thereto |
Hwai-Jong Cheng |
1998-08-18 |
|
| 5789182 |
System for assaying binding to a heparin-binding growth factor receptor |
Avner Yayon, David M. Ornitz, Michael Klagsbrun, Philip Leder |
1998-08-04 |
|
